ClinicalTrials.gg
TerminatedNCT06320080Updated Nov 21, 2025

Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.

A Phase 1 interventional study of TQB2223 injection and Penpulimab Injection in Advanced Hepatocellular Carcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Why this study was terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
886th of 1,034
22 · median 78
Started
2024
with 139 others
Phase 1
138 of 1,310
60 open now
Registered
923rd of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 886th largest by enrollment of the 1,034 interventional ones that give a count, is one of 140 that started in 2024, is one of 138 in phase 1, and was the 923rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. This is a phase Ib study aimed at evaluating the safety, tolerability, and immunogenicity characteristics of TQB2223 injection combined with AK105 injection in the treatment of advanced hepatocellular carcinoma.

03

Conditions studied

  • Advanced Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 75 years old, an (ECOG) performance status of 0 to 1, and ≥3 months;
  • Hepatocellular carcinoma (HCC) patients confirmed by pathological histology or cytology examination or meeting the clinical diagnostic criteria for hepatocellular carcinoma according to the American Association for the Study of Liver Diseases (AASLD) or the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2022 edition);
  • Have not received any immunotherapy for advanced HCC previously;
  • Subjects with a China liver cancer staging (CNLC) of stage III [or Barcelona clinical staging of liver cancer (BCLC) of stage C], or CNLC-II (BCLC-B) subjects who are not suitable for local treatment (such as hepatic artery chemotherapy and embolization) and surgical treatment, or cannot benefit from local treatment and surgical treatment as determined by the investigators;
  • liver function grading: Grade A or B (≤ 7 points)
  • Subjects with advanced malignant tumors who failed standard treatment or lacked effective treatment;
  • The main organs function well;
  • Male or female patient had no plans to become pregnant and agree to voluntarily take effective measures during the study to at least 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Concurrent secondary or other malignancy with no evidence of disease within 5 years prior to the first dose;
  • Within 28 days prior to the first dose, received significant surgical treatment, or with obvious traumatic injury or long-term unhealed wound or fracture;
  • Patients who experienced any bleeding or bleeding events ≥ CTC AE level 3 within 4 weeks prior to the first dose; Individuals who have experienced arterial/venous thrombosis events within 6 months prior to the first dose, such as cerebrovascular accidents, deep vein thrombosis, and pulmonary embolism; Low molecular weight heparin treatment is allowed, and antiplatelet drugs are prohibited throughout the entire study period;
  • A history of gastrointestinal bleeding such as active gastric and duodenal ulcers, persistent positive fecal occult blood, and ulcerative colitis within 6 months prior to the first dose; Or other conditions determined by investigators that may cause gastrointestinal bleeding or perforation;
  • Patients with portal hypertension and at high risk of bleeding considered by the investigators, or have been confirmed by gastroscopy to have red signs or severe esophageal and gastric varicose veins.
  • Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;
  • Individuals who have previously received or are preparing to undergo bone marrow transplantation or solid organ transplantation within 6 months;
  • History of hepatic encephalopathy;
  • History of uncontrolled intercurrent illness;
  • Participants who have participated in other clinical trials of anti-tumor drugs and used other anti-tumor drugs within 4 weeks prior to the first dose;
  • Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    TQB2223 injection+ AK105 Injection

    TQB2223 injection combined with AK105 (Penpulimab) injection, once every three weeks. 21 days as a treatment cycle.

    Drug: TQB2223 injection · Drug: Penpulimab Injection

Interventions

  • DrugTQB2223 injection

    TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.

  • Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    The percentage of subjects with Complete Response (CR) or partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 and Immune-Modified Response Evaluation Criteria In Solid Tumors (iRECIST).

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks.

  2. Progression-free survival (PFS)

    The time from the first dose of TQB2223 to the first occurrence of disease progression or death from any cause.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

Secondary outcomes

  1. Overall survival (OS)

    The time from the first treatment to death from any cause.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

  2. Disease control rate (DCR)

    The proportion of subjects with Complete response (CR), Partial response (PR), or Stable Disease (SD).

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

  3. Duration of Response (DOR)

    The time from first documented response to documented disease progression or death.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

  4. Number of patients with adverse events (AEs) and/or serious adverse events (SAEs)

    Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: From the time of informed consent to 28 days after the last dose

  5. Immunogenicity

    The occurence of Anti-drug antibody (ADA) after administration

    Time frame: within 1 hour before dose in the 1st, 2nd, 4th, and 8th cycle. 30 and 90 days after the last dose. 21 days as a treatment cycle.

07

Study locations

3 sites
  • Affiliated Cancer Hospital of Harbin Medical University
    Harbin, Heilongjiang 150000, China
  • Hubei Provincial Tumor Hospital
    Wuhan, Hubei 430079, China
  • Hunan Provincial Tumor Hospital
    Changsha, Hunan 410031, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Nov 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 20, 2024
StartActual
May 30, 2024
Primary completionActual
Nov 3, 2025
CompletionActual
Nov 3, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06320080
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
May 30, 2024
Primary completion
Nov 3, 2025
Completion
Nov 3, 2025
Last update
Nov 21, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Penpulimab

Start the discussion